EPB41L3 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant EPB41L3.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, E |
---|---|
Primary Accession | Q9Y2J2 |
Other Accession | NM_012307 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 2B1 |
Calculated MW | 120678 Da |
Gene ID | 23136 |
---|---|
Other Names | Band 41-like protein 3, 41B, Differentially expressed in adenocarcinoma of the lung protein 1, DAL-1, Band 41-like protein 3, N-terminally processed, EPB41L3, DAL1, KIAA0987 |
Target/Specificity | EPB41L3 (NP_036439, 915 a.a. ~ 1007 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | EPB41L3 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
1.The tale of two domains: Proteomic and genomic analysis of SMYD2, a new histone methyltransferase.Abu-Farha M, Lambert JP, Al-Madhoun AS, Elisma F, Skerjanc IS, Figeys D.Mol Cell Proteomics. 2008 Mar;7(3):560-72. Epub 2007 Dec 7.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.